DK1951296T3 - Celleafledte virale vacciner med lave niveauer af restcelle-DNA - Google Patents

Celleafledte virale vacciner med lave niveauer af restcelle-DNA

Info

Publication number
DK1951296T3
DK1951296T3 DK06831855.9T DK06831855T DK1951296T3 DK 1951296 T3 DK1951296 T3 DK 1951296T3 DK 06831855 T DK06831855 T DK 06831855T DK 1951296 T3 DK1951296 T3 DK 1951296T3
Authority
DK
Denmark
Prior art keywords
cell
dna
cell culture
low levels
residual
Prior art date
Application number
DK06831855.9T
Other languages
English (en)
Other versions
DK1951296T4 (da
Inventor
Jens-Peter Gregersen
Holger Kost
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1951296(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of DK1951296T3 publication Critical patent/DK1951296T3/da
Application granted granted Critical
Publication of DK1951296T4 publication Critical patent/DK1951296T4/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06831855.9T 2005-11-01 2006-11-01 Celleafledte viral vacciner med lave niveauer af restcelle-DNA DK1951296T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (2)

Publication Number Publication Date
DK1951296T3 true DK1951296T3 (da) 2011-03-28
DK1951296T4 DK1951296T4 (da) 2014-09-01

Family

ID=37969762

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06831855.9T DK1951296T4 (da) 2005-11-01 2006-11-01 Celleafledte viral vacciner med lave niveauer af restcelle-DNA

Country Status (19)

Country Link
US (2) US10655108B2 (da)
EP (3) EP2842572A1 (da)
JP (5) JP5602366B2 (da)
KR (1) KR20080081254A (da)
CN (2) CN101365480B (da)
AT (1) ATE494906T1 (da)
AU (2) AU2006310171B2 (da)
CA (1) CA2627971A1 (da)
CY (1) CY1111378T1 (da)
DE (1) DE602006019629D1 (da)
DK (1) DK1951296T4 (da)
EA (1) EA014062B1 (da)
ES (2) ES2525518T3 (da)
HK (2) HK1129837A1 (da)
NZ (1) NZ567817A (da)
PL (2) PL2301572T3 (da)
PT (1) PT2301572E (da)
SI (1) SI1951296T2 (da)
WO (1) WO2007052163A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567817A (en) * 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
DK1976559T6 (da) 2006-01-27 2020-04-06 Seqirus Uk Ltd Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
CA2663196A1 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
EA201070066A1 (ru) * 2007-06-27 2010-06-30 Новартис Аг Вакцины против гриппа с низким содержанием добавок
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2268309B1 (en) * 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
US20110217330A1 (en) 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
DE102010018462A1 (de) 2009-04-27 2011-04-07 Novartis Ag Impfstoffe zum Schutz gegen Influenza
SI2401384T1 (sl) 2009-05-21 2013-01-31 Novartis Ag Reverzna genetika z uporabo neendogenih pol i promotorjev
CA2769673A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
EP2485764A4 (en) 2009-10-09 2014-01-29 Childrens Medical Center WHOLE CELL VACCINE WITH SELECTIVE DISSOCIATION
AU2010309404B2 (en) 2009-10-20 2015-07-09 Seqirus UK Limited Improved reverse genetics methods for virus rescue
CN102858961A (zh) 2010-05-03 2013-01-02 葛兰素史密丝克莱恩生物有限公司 新方法
BR112012028146A2 (pt) * 2010-05-06 2015-09-15 Novartis Ag compostos de peróxido orgânico para inativação de microorganismos
EP2571520B1 (en) 2010-05-21 2018-04-04 Seqirus UK Limited Influenza virus reassortment method
JP5976639B2 (ja) 2010-06-01 2016-08-23 ノバルティス アーゲー インフルエンザワクチン抗原の濃縮および凍結乾燥
PL2575872T3 (pl) 2010-06-01 2021-02-22 Seqirus UK Limited Zatężanie antygenów szczepionkowych grypy bez liofilizacji
CN103052399B (zh) 2010-08-12 2016-06-29 依生生物制药控股有限公司 用于减少病毒组合物中dna杂质的方法
AU2011290471B2 (en) 2010-08-20 2015-08-20 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
AU2012221740B2 (en) 2011-02-25 2016-11-17 Novartis Ag Exogenous internal positive control
MY172501A (en) 2011-11-03 2019-11-27 Sentinext Therapeutics Sdn Bhd Vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
AU2013205478B9 (en) 2012-03-02 2014-11-20 Seqirus UK Limited Influenza virus reassortment
CA2866465A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
AU2013270793A1 (en) 2012-06-04 2014-12-11 Novartis Ag Improved safety testing
AU2013354219A1 (en) 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
WO2014141125A2 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
EP2801372A3 (en) 2013-05-10 2015-02-18 Novartis AG Avoiding narcolepsy risk in influenza vaccines
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
MX2015016755A (es) 2013-06-06 2016-04-13 Novartis Ag Reagrupamiento del virus de influenza.
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
WO2015071177A1 (en) 2013-11-15 2015-05-21 Novartis Ag Removal of residual cell culture impurities
TWI688652B (zh) * 2014-05-28 2020-03-21 財團法人國家衛生研究院 作為對抗腸病毒感染之免疫原的病毒顆粒及其製造
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
HUE051783T2 (hu) 2015-07-07 2021-03-29 Seqirus Uk Ltd Eljárás immunogén hemagglutinin mennyiségi meghatározására
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (da) * 1974-01-14 1977-07-15 Sandoz Ag
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
DE3788902T3 (de) 1986-06-17 2004-11-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung.
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ha蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
JP3108480B2 (ja) 1991-09-25 2000-11-13 松下電工株式会社 多重伝送システムの割込処理方法
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
CA2332455C (en) * 1998-06-01 2012-08-14 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
PL355287A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
AU3241501A (en) 1999-12-08 2001-06-18 Crucell Holland B.V. Method of administering adenovirus
DE60142506D1 (de) 2000-03-03 2010-08-19 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
EP1361889A1 (en) 2001-02-23 2003-11-19 GlaxoSmithKline Biologicals S.A. Novel vaccine
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
WO2002087494A2 (en) 2001-04-27 2002-11-07 Glaxosmithkline Biologicals, Sa Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
WO2003091401A2 (en) * 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
AU2003299244A1 (en) 2002-12-20 2004-07-14 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
WO2004112831A2 (en) 2003-05-28 2004-12-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
CN101094915A (zh) 2004-05-20 2007-12-26 益得生物医学公司 生产流感疫苗的方法
DE602005024827D1 (de) * 2004-09-09 2010-12-30 Novartis Vaccines & Diagnostic Verminderung von potentiellen iatrogenen risiken in verbindung mit influenza impfstoffen
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
EP1831353B1 (en) 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
NZ567817A (en) * 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment

Also Published As

Publication number Publication date
PL1951296T5 (pl) 2015-06-30
WO2007052163A3 (en) 2007-09-07
US11466257B2 (en) 2022-10-11
KR20080081254A (ko) 2008-09-09
ES2359214T5 (es) 2014-10-08
JP6639077B2 (ja) 2020-02-05
EP2301572B1 (en) 2014-09-10
JP2016185988A (ja) 2016-10-27
AU2006310171B2 (en) 2011-02-17
BRPI0618094A2 (pt) 2011-08-16
SI1951296T2 (sl) 2014-09-30
HK1207828A1 (en) 2016-02-12
WO2007052163A2 (en) 2007-05-10
ES2525518T3 (es) 2014-12-26
DK1951296T4 (da) 2014-09-01
EP2301572A1 (en) 2011-03-30
CY1111378T1 (el) 2015-08-05
US20090304729A1 (en) 2009-12-10
DE602006019629D1 (de) 2011-02-24
CN104474543A (zh) 2015-04-01
CN101365480A (zh) 2009-02-11
ATE494906T1 (de) 2011-01-15
JP5602366B2 (ja) 2014-10-08
EP2842572A1 (en) 2015-03-04
EP1951296B2 (en) 2014-07-23
JP2009513694A (ja) 2009-04-02
EP1951296B1 (en) 2011-01-12
AU2006310171A1 (en) 2007-05-10
JP2014198726A (ja) 2014-10-23
EA014062B1 (ru) 2010-08-30
HK1129837A1 (en) 2009-12-11
US10655108B2 (en) 2020-05-19
JP2020023557A (ja) 2020-02-13
NZ567817A (en) 2012-01-12
EA200801221A1 (ru) 2008-10-30
CN101365480B (zh) 2014-11-05
BRPI0618094A8 (pt) 2017-08-22
PL1951296T3 (pl) 2011-09-30
AU2011201968B2 (en) 2014-08-28
EP1951296A2 (en) 2008-08-06
SI1951296T1 (sl) 2011-04-29
JP2011256209A (ja) 2011-12-22
PT2301572E (pt) 2014-12-22
JP7049761B2 (ja) 2022-04-07
PL2301572T3 (pl) 2015-02-27
US20200377864A1 (en) 2020-12-03
AU2011201968A1 (en) 2011-05-19
ES2359214T3 (es) 2011-05-19
CA2627971A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
DK1951296T4 (da) Celleafledte viral vacciner med lave niveauer af restcelle-DNA
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
MX2012001592A (es) Composicion para el tratamiento de la infección del virus de la hepatitis b.
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201390538A1 (ru) Противовирусные соединения
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
WO2007024941A3 (en) Polyvalent vaccine
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
WO2012061815A3 (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
WO2010019262A3 (en) Polyvalent vaccine
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
AR061894A1 (es) Vacunas para malaria
UA108902C2 (uk) Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
WO2010001409A3 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
WO2010095041A3 (en) Compositions, methods, and kits for treating influenza viral infections
ME01140B (me) Virus goveđe virusne dijareje s modifikovanim erns proteinom
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
TW200531701A (en) Method of vaccination against testicular BVDV infection
WO2007028985A3 (en) Adjuvanted vaccine
WO2007104263A8 (zh) 一种乙型肝炎病毒疫苗增效蛋白及其基因
TR201905336T4 (tr) Rekombinant rsv antijenleri.